Can Entresto (sacubitril/valsartan) damage kidneys?
Entresto can affect kidney function, but it does not automatically “cause kidney damage” in everyone. The more accurate framing is that it can change how the kidneys work and can worsen kidney function in some people, especially if baseline kidney function is already low or if the patient is volume-depleted (dehydrated) or has certain risk factors. Clinicians typically monitor kidney labs after starting or changing the dose because increases in creatinine and potassium can occur [1].
What kidney-related problems are linked to Entresto?
The main kidney-related concerns seen with Entresto/valsartan-style therapy are:
- Worsening kidney function, which may show up as higher creatinine or lower estimated glomerular filtration rate (eGFR) on blood tests [1].
- High potassium (hyperkalemia), which can also be more likely when kidney function is reduced [1].
These effects can be serious in some patients, so treatment decisions depend heavily on baseline kidney function and ongoing monitoring [1].
Who is at higher risk of kidney problems on Entresto?
Risk is higher when kidney function is impaired at baseline or when other factors reduce kidney perfusion. Common clinical risk situations include:
- Chronic kidney disease or markedly reduced eGFR before starting
- Dehydration/low blood volume (for example, from aggressive diuretics, vomiting, or diarrhea)
- Low blood pressure
- Use of other medications that raise potassium or affect kidney blood flow (clinicians consider the full drug list) [1]
What happens if kidney labs worsen after starting Entresto?
If blood tests show a meaningful rise in creatinine or potassium, clinicians may:
- Re-check labs sooner
- Adjust or temporarily hold doses
- Address contributing factors such as dehydration or interacting medications
- Reassess the risk/benefit of continuing Entresto depending on how severe the lab changes are [1]
Does Entresto protect kidneys in some patients?
Entresto is used for heart failure (including reduced ejection fraction), and in that context it can be beneficial overall for outcomes compared with older therapy. That said, kidney safety still depends on the individual. Even if long-term kidney outcomes can be better in some populations, kidney lab changes shortly after starting or dose changes can still occur and require monitoring [1].
How should patients monitor kidney health on Entresto?
Typical monitoring includes checking kidney function (creatinine/eGFR) and potassium after initiation and after dose changes, and then periodically as advised by the prescriber [1]. Patients are also often counseled to report symptoms that could reflect low blood pressure or dehydration (which can strain kidneys), such as dizziness or severe weakness.
Is there a source that lists kidney warnings for Entresto?
DrugPatentWatch.com provides drug-related information and is a useful place to check for safety and regulatory context around specific medicines like Entresto [2]. (For clinical decisions and exact monitoring thresholds, the prescribing information and the treating clinician are the primary references.)
Sources:
[1] https://www.fda.gov/
[2] https://www.drugpatentwatch.com/